{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:45:27Z","timestamp":1776840327724,"version":"3.51.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid hormone receptor-interacting protein 13 (TRIP13), an enzyme from the AAA-ATPase family, facilitates the assembly or disassembly of protein complexes and participates in various biological processes. However, its impact on cancer immune infiltration and pan-cancer prognosis remains largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Pan-cancer multi-omics data from publicly available resources were systematically analyzed to evaluate TRIP13 expression across various cancer types and its association with patient prognosis. In addition, functional enrichment analyses were conducted to investigate TRIP13-related biological processes and pathways. The analysis included GSEA enrichment, correlation with immune regulator expression, tumor immune cell infiltration, association with tumor mutational burden (TMB), and correlation with microsatellite instability (MSI). Additionally, single-cell data were used to explore the expression and potential role of TRIP13 at the single-cell level. We subsequently conducted a series of\n                      <jats:italic>in vitro<\/jats:italic>\n                      experiments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our comprehensive pan-cancer analysis reveals significantly elevated TRIP13 expression across multiple cancer types and links it to poor prognostic outcomes. TRIP13 primarily activates pathways such as ubiquitination, cell cycle regulation, and DNA repair to drive tumor progression. Additionally, TRIP13 expression exhibits complex associations with various immune regulators and immune cells. In prostate cancer, TRIP13 shows marked overexpression and is associated with unfavorable prognosis. We identified a significant upregulation of TRIP13 in proliferative tumor stem-like populations in prostate cancer. Consistently, prostate cancer cells that acquired resistance to CDK4\/6 inhibitors displayed marked TRIP13 overexpression, and functional assays revealed that TRIP13 modulates cellular sensitivity to these agents. Mechanistically, we demonstrated that E2F1 transcriptionally activates TRIP13, which in turn drives the upregulation of the downstream ubiquitin ligase HECTD3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study reveals aberrant TRIP13 expression across multiple cancers and its association with immune modulation and tumor aggressiveness. The elevation of TRIP13 in palbociclib resistant prostate cancer, together with the regulatory E2F1\u2013TRIP13\u2013HECTD3 axis, highlights its potential as a prognostic biomarker and therapeutic target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1691436","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:48:03Z","timestamp":1776836883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuanqiao","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruilin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinhuai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1381920","article-title":"Causal relationship between immune cells and prostate cancer: a Mendelian randomization study","volume":"12","author":"Ye","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced Prostate Cancer: Treatment Advances and Future Directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12967-022-03860-3","article-title":"Wang Y et\u00a0al: Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.09.028","article-title":"Cancer stem cell plasticity in shaping drug resistance landscapes in prostate cancer","author":"Zhang","year":"2025","journal-title":"J Adv Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002611","article-title":"Prostate cancer stem cell dynamics in the evolution of drug resistance","volume":"111","author":"Zhang","year":"2025","journal-title":"Int J Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146893","article-title":"Gai D et\u00a0al: TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies","volume":"131","author":"Li","year":"2021","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17278","article-title":"Liu L et\u00a0al: Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways","volume":"26","author":"Lan","year":"2022","journal-title":"J Cell Mol Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.06.009","article-title":"Nyati MK et\u00a0al: Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab","volume":"30","author":"Banerjee","year":"2022","journal-title":"Mol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12821","article-title":"TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status","volume":"14","author":"Agarwal","year":"2020","journal-title":"Mol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202104291","article-title":"Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death","volume":"9","author":"Rios Garcia","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.09.168","article-title":"TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer","volume":"121","author":"Dong","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00820-2","article-title":"Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers","volume":"5","author":"Dong","year":"2024","journal-title":"Nat Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0316","article-title":"Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.80017","article-title":"Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response","volume":"19","author":"Zheng","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41419-024-07012-x","article-title":"TRIP13 regulates progression of gastric cancer through stabilising the expression of DDX21","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.11.004","article-title":"Tetrahydrocurcumin targets TRIP13 inhibiting the interaction of TRIP13\/USP7\/c-FLIP to mediate c-FLIP ubiquitination in triple-negative breast cancer","volume":"75","author":"Sun","year":"2024","journal-title":"J Adv Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146893","article-title":"TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies","volume":"131","author":"Li","year":"2021","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1038\/s41467-021-25724-y","article-title":"MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair","volume":"12","author":"de Krijger","year":"2021","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-019-0442-y","article-title":"TRIP13 regulates DNA repair pathway choice through REV7 conformational change","volume":"22","author":"Clairmont","year":"2020","journal-title":"Nat Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3364","article-title":"E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer","volume":"48","author":"Liang","year":"2016","journal-title":"Int J Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2023.0202","article-title":"Li G et\u00a0al: Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 Expression","volume":"14","author":"Song","year":"2023","journal-title":"Aging Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cell.2018.07.015","article-title":"Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import","volume":"174","author":"Rodriguez-Bravo","year":"2018","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302368","article-title":"Targeting CBX3 with a Dual BET\/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4\/6 Inhibitors in Prostate Cancer","volume":"10","author":"Liang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41420-024-02154-5","article-title":"Targeting the HECTD3-p62 axis increases the radiosensitivity of triple negative breast cancer cells","volume":"10","author":"Huang","year":"2024","journal-title":"Cell Death Discov"},{"key":"B33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2017.09.048","article-title":"Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment","volume":"411","author":"Shu","year":"2017","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1272108","article-title":"A pan-cancer analysis of the prognostic implication and oncogenic role of tubulin epsilon and delta complex 2 (TEDC2) in human tumors","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100951","DOI":"10.1016\/j.neo.2023.100951","article-title":"Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma","volume":"47","author":"Afaq","year":"2024","journal-title":"Neoplasia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41419-024-06433-y","article-title":"Germline specific genes increase DNA double-strand break repair and radioresistance in lung adenocarcinoma cells","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41420-022-01001-9","article-title":"HECTD3 promotes gastric cancer progression by mediating the polyubiquitination of c-MYC","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Death Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1691436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:48:04Z","timestamp":1776836884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1691436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1691436"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1691436","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1691436"}}